Carregant...
Comparative outcomes in patients receiving pirfenidone or nintedanib for idiopathic pulmonary fibrosis
BACKGROUND: Real-world data regarding outcomes of idiopathic pulmonary fibrosis (IPF) are scarce, outside of registries. In France, pirfenidone and nintedanib are only reimbursed for documented IPF, with similar reimbursement criteria with respect to disease characteristics, prescription through a d...
Guardat en:
| Publicat a: | Respir Res |
|---|---|
| Autors principals: | , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioMed Central
2021
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8094468/ https://ncbi.nlm.nih.gov/pubmed/33947414 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12931-021-01714-y |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|